355 related articles for article (PubMed ID: 15380336)
1. Effects of the IMP-dehydrogenase inhibitor, Tiazofurin, in bcr-abl positive acute myelogenous leukemia. Part II. In vitro studies.
Wright DG; Boosalis M; Malek K; Waraska K
Leuk Res; 2004 Nov; 28(11):1137-43. PubMed ID: 15380336
[TBL] [Abstract][Full Text] [Related]
2. Tiazofurin effects on IMP-dehydrogenase activity and expression in the leukemia cells of patients with CML blast crisis.
Wright DG; Boosalis MS; Waraska K; Oshry LJ; Weintraub LR; Vosburgh E
Anticancer Res; 1996; 16(6A):3349-51. PubMed ID: 9042310
[TBL] [Abstract][Full Text] [Related]
3. Effects of the IMP-dehydrogenase inhibitor, Tiazofurin, in bcr-abl positive acute myelogenous leukemia. Part I. In vivo studies.
Malek K; Boosalis MS; Waraska K; Mitchell BS; Wright DG
Leuk Res; 2004 Nov; 28(11):1125-36. PubMed ID: 15380335
[TBL] [Abstract][Full Text] [Related]
4. p210 bcr-abl confers overexpression of inosine monophosphate dehydrogenase: an intrinsic pathway to drug resistance mediated by oncogene.
Gharehbaghi K; Burgess GS; Collart FR; Litz-Jackson S; Huberman E; Jayaram HN; Boswell HS
Leukemia; 1994 Aug; 8(8):1257-63. PubMed ID: 7520100
[TBL] [Abstract][Full Text] [Related]
5. Induction of cell differentiation in melanoma cells by inhibitors of IMP dehydrogenase: altered patterns of IMP dehydrogenase expression and activity.
Kiguchi K; Collart FR; Henning-Chubb C; Huberman E
Cell Growth Differ; 1990 Jun; 1(6):259-70. PubMed ID: 1980599
[TBL] [Abstract][Full Text] [Related]
6. Biochemically targeted therapy of refractory leukemia and myeloid blast crisis of chronic granulocytic leukemia with Tiazofurin, a selective blocker of inosine 5'-phosphate dehydrogenase activity.
Tricot G; Weber G
Anticancer Res; 1996; 16(6A):3341-7. PubMed ID: 9042309
[TBL] [Abstract][Full Text] [Related]
7. Biochemical consequences of resistance to a recently discovered IMP dehydrogenase inhibitor, benzamide riboside, in human myelogenous leukemia K562 cells.
Jayaram HN; O'Connor A; Grant MR; Yang H; Grieco PA; Cooney DA
J Exp Ther Oncol; 1996 Sep; 1(5):278-85. PubMed ID: 9414415
[TBL] [Abstract][Full Text] [Related]
8. Consequences of IMP dehydrogenase inhibition, and its relationship to cancer and apoptosis.
Jayaram HN; Cooney DA; Grusch M; Krupitza G
Curr Med Chem; 1999 Jul; 6(7):561-74. PubMed ID: 10390601
[TBL] [Abstract][Full Text] [Related]
9. Cytotoxicity of a new IMP dehydrogenase inhibitor, benzamide riboside, to human myelogenous leukemia K562 cells.
Jayaram HN; Gharehbaghi K; Jayaram NH; Rieser J; Krohn K; Paull KD
Biochem Biophys Res Commun; 1992 Aug; 186(3):1600-6. PubMed ID: 1354960
[TBL] [Abstract][Full Text] [Related]
10. IMP dehydrogenase inhibitor, tiazofurin, induces apoptosis in K562 human erythroleukemia cells.
Vitale M; Zamai L; Falcieri E; Zauli G; Gobbi P; Santi S; Cinti C; Weber G
Cytometry; 1997 Feb; 30(1):61-6. PubMed ID: 9056744
[TBL] [Abstract][Full Text] [Related]
11. Tiazofurin: biological effects and clinical uses.
Tricot G; Jayaram HN; Weber G; Hoffman R
Int J Cell Cloning; 1990 May; 8(3):161-70. PubMed ID: 2189014
[TBL] [Abstract][Full Text] [Related]
12. Biochemically directed therapy of leukemia with tiazofurin, a selective blocker of inosine 5'-phosphate dehydrogenase activity.
Tricot GJ; Jayaram HN; Lapis E; Natsumeda Y; Nichols CR; Kneebone P; Heerema N; Weber G; Hoffman R
Cancer Res; 1989 Jul; 49(13):3696-701. PubMed ID: 2567208
[TBL] [Abstract][Full Text] [Related]
13. Nucleoside and non-nucleoside IMP dehydrogenase inhibitors as antitumor and antiviral agents.
Franchetti P; Grifantini M
Curr Med Chem; 1999 Jul; 6(7):599-614. PubMed ID: 10390603
[TBL] [Abstract][Full Text] [Related]
14. Selective up-regulation of type II inosine 5'-monophosphate dehydrogenase messenger RNA expression in human leukemias.
Nagai M; Natsumeda Y; Konno Y; Hoffman R; Irino S; Weber G
Cancer Res; 1991 Aug; 51(15):3886-90. PubMed ID: 1677309
[TBL] [Abstract][Full Text] [Related]
15. Comparison of biochemical parameters of benzamide riboside, a new inhibitor of IMP dehydrogenase, with tiazofurin and selenazofurin.
Gharehbaghi K; Sreenath A; Hao Z; Paull KD; Szekeres T; Cooney DA; Krohn K; Jayaram HN
Biochem Pharmacol; 1994 Oct; 48(7):1413-9. PubMed ID: 7945441
[TBL] [Abstract][Full Text] [Related]
16. Biochemical consequences of resistance to tiazofurin in human myelogenous leukemic K562 cells.
Jayaram HN; Zhen W; Gharehbaghi K
Cancer Res; 1993 May; 53(10 Suppl):2344-8. PubMed ID: 8097964
[TBL] [Abstract][Full Text] [Related]
17. Molecular targets of guanine nucleotides in differentiation, proliferation and apoptosis.
Yalowitz JA; Jayaram HN
Anticancer Res; 2000; 20(4):2329-38. PubMed ID: 10953293
[TBL] [Abstract][Full Text] [Related]
18. Effects of tiazofurin on globin and proto-oncogene expression in K562 erythroleukemia cells.
Kharbanda SM; Miyazaki K; Takeyama H; Sherman ML; Spriggs DR; Carney WP; Kufe DW
Cancer Commun; 1989; 1(3):191-7. PubMed ID: 2639729
[TBL] [Abstract][Full Text] [Related]
19. Antitumor effects of celecoxib on K562 leukemia cells are mediated by cell-cycle arrest, caspase-3 activation, and downregulation of Cox-2 expression and are synergistic with hydroxyurea or imatinib.
Zhang GS; Liu DS; Dai CW; Li RJ
Am J Hematol; 2006 Apr; 81(4):242-55. PubMed ID: 16550520
[TBL] [Abstract][Full Text] [Related]
20. IMP dehydrogenase basal activity in MOLT-4 human leukaemia cells is altered by mycophenolic acid and 6-thioguanosine.
Vethe NT; Bremer S; Bergan S
Scand J Clin Lab Invest; 2008; 68(4):277-85. PubMed ID: 18609073
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
